Arthneeti

SMS Pharmaceuticals Q1 FY27 Share Price & Earnings Call Analysis

₹485.80+2.18% today
Market cap
₹4,550 Cr
P/E
44.44
ROE
14.31%
PEG
0.29
Price to sales
5.06
Debt to equity
0.46
52W high / low
₹486 / ₹272
Sales growth (5Y)
9.51%
EBITDA margin
19.26%
Net profit margin
11.50%
Promoter holding
68.07%
Sales (last year)
₹898 Cr

SMS Pharmaceuticals Ltd is a diversified and integrated pharmaceutical company with interests in Active Pharmaceutical Ingredients (API) and Intermediates.[1]

Guidance scorecard · Q1 FY27 call

What SMS Pharma.'s management guided
and where it ranks in Pharmaceuticals & Biotechnology

#40of 83 in
Pharmaceuticals & Biotechnology
Revenue10–20%MarginsUp 2%+CapexPlannedFundraisingWhat management saidOrder bookWhat management said

RevenueQ4 FY26 call

10–20%
  • FY27 revenue growth guidance is 15%, adopting a prudent approach due to geopolitical uncertainties impacting logistics and supply chains.
  • If external environment stabilizes, growth could exceed current guidance thanks to strong product opportunities.
  • Targeted long-term growth rate is 20%-25% annually post-FY27.
  • Installed capacity to increase to 800 metric tons per month by FY27-end; high utilization expected by FY28, supporting volume growth.
  • Continued focus on expanding product portfolio including 4-5 new APIs and brownfield expansion expected to contribute significantly from FY28 onwards.
  • Backward integration (notably ibuprofen) to improve margins and sales sustainability.

2 more points from SMS Pharma.'s call on revenue

Create a free account to keep reading this call

Full Q4 FY26 analysis

MarginsQ4 FY26 call

Up 2%+

See what SMS Pharma. said on margins — free account, 30 seconds.

Full Q4 FY26 analysis

CapexQ4 FY26 call

Planned
  • Ongoing brownfield expansion project with a planned investment of approximately INR 280 crores; INR 130 crores already invested.
  • Expansion includes building a dedicated block for 4-5 new high-margin APIs to support commercialization.
  • Increasing ibuprofen backward integration capacity from 500 to 800 metric tons per month; current capacity utilization around 80%.
  • Capex work expected to be completed by March FY27; incremental revenues anticipated from FY28.
  • Focus on backward integration to improve margins and stabilize supply, especially for key products like ibuprofen.

2 more points from SMS Pharma.'s call on capex

Create a free account to keep reading this call

Full Q4 FY26 analysis

FundraisingQ4 FY26 call

See what SMS Pharma. said on fundraising — free account, 30 seconds.

Full Q4 FY26 analysis

Order bookQ4 FY26 call

  • There is mention of strong growth and high capacity utilization, particularly for anti-inflammatory APIs, with a significant portion of planned capacity already committed for the coming year.
  • The company expects capacity utilization to reach a high level by FY28 after completion of capex in FY27.
  • New product filings and expansions (including 12 DMFs filed in FY26 and plans for 10 filings in FY27 and FY28 each) indicate a healthy pipeline for future orders.
  • Joint venture products are being developed and expected to commercialize within the financial year, supporting new order inflows.
Full Q4 FY26 analysis
Full Pharmaceuticals & Biotechnology ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does SMS Pharma. rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹556 Cr22.1
240%+Up 0–2%₹215 Cr22.2
340%+Flat₹16,144 Cr—
440%+Flat₹6,072 Cr48.0
540%+Flat₹40 Cr—
620–40%Up 2%+₹50,220 Cr43.8

Sign up free to see every company in the sector ranking and track SMS Pharma..

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of SMS Pharma.

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of SMS Pharma.

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +149135167161246164197173248196242210238
Expenses +126109139133212131165140207157194167198
Operating Profit23272829333332334139484440
OPM %16%20%17%18%14%20%16%19%17%20%20%21%17%
Other Income +1111211211143
Interest6666655456665
Depreciation88888899910101010
Profit before tax11131516222220232924343127
Tax %24%29%21%26%26%25%28%24%29%24%26%25%23%
Net Profit +891212161614172118252321
EPS in Rs0.951.101.421.441.881.931.682.032.332.052.682.492.23

Financials of SMS Pharma.

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +587611438463465412563520522709783887
Expenses +500522363369375332442405467592643716
Operating Profit86897593908012111555117140171
OPM %15%15%17%20%19%19%22%22%10%16%18%19%
Other Income +1641235355468
Interest181716151212111922241923
Depreciation171919201922223232323440
Profit before tax675642606251916966693116
Tax %48%26%14%33%34%36%33%1%26%25%27%25%
Net Profit +35423640413361684496888
EPS in Rs4.154.924.204.784.893.867.208.030.485.837.719.35
Dividend Payout %5%4%5%5%5%6%4%4%62%7%5%4%

Financials of SMS Pharma.

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital888888888899
Reserves246286254293331359420485487562664795
Borrowings +167204149146144157255263254281311365
Other Liabilities +119158897293103147126165217202211
Total Liabilities5406565015195776278308839141,0681,1861,381
Fixed Assets +277370290279281280457438412437533534
CWIP2913881842711333035116
Investments132137454545454545454552
Other Assets +221252166187232259321389424556573679
Total Assets5406565015195776278308839141,0681,1861,381

Financials of SMS Pharma.

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +596173325040904522508261
Cash from Investing Activity +-55-79-39-17-35-43-152-27-30-52-123-132
Cash from Financing Activity +-1027-33-15-13-292-12-32314776
Net Cash Flow-69102-5316-392954
Free Cash Flow11-27502315-3-6118-7-2-42-64
CFO/OP75%93%110%46%70%65%88%52%49%56%73%50%

Financials of SMS Pharma.

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days37361819204368341041229589
Inventory Days81106114135170191148333243201238259
Days Payable58798249596670971171309589
Cash Conversion Cycle616350105131169146270230192238259
Working Capital Days1919-22739574894104858898
ROCE %21%16%13%18%16%13%17%12%4%11%12%13%

Guidance history

How SMS Pharma.'s guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q4 FY26 call →10–20%Up 2%+Planned——
Q2 FY26 call →20–40%Up 2%+Planned—Rising

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

84out of 100

Momentum score · price trend

84 out of 100 — Strengthening

Over the past year its share price has done better than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months+68.4%89%
Last 6 months+20.3%74%
Last 3 months+29.7%91%
How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For SMS Pharma.: 0.4 × 89 + 0.4 × 74 + 0.2 × 91 = 84.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What SMS Pharma.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Lincoln Pharmaceuticals Ltd (Q2 FY27)

    2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it

  • Alivus Life Sciences Ltd (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest

  • Strides Pharma Science Ltd (Q2 FY27)

    Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation

  • Laurus Labs Ltd (Q2 FY27)

    2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd